The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
12 Apr 2024
12 Apr 2024
Historique:
medline:
12
4
2024
pubmed:
12
4
2024
entrez:
12
4
2024
Statut:
aheadofprint
Résumé
BK polyomavirus (BKPyV) remains a significant challenge after kidney transplantation. International experts reviewed current evidence and updated recommendations according to Grading of Recommendations, Assessment, Development, and Evaluations (GRADE). Risk factors for BKPyV-DNAemia and biopsy-proven BKPyV-nephropathy include recipient older age, male sex, donor BKPyV-viruria, BKPyV-seropositive donor/-seronegative recipient, tacrolimus, acute rejection, and higher steroid exposure. To facilitate early intervention with limited allograft damage, all kidney transplant recipients should be screened monthly for plasma BKPyV-DNAemia loads until month 9, then every 3 mo until 2 y posttransplant (3 y for children). In resource-limited settings, urine cytology screening at similar time points can exclude BKPyV-nephropathy, and testing for plasma BKPyV-DNAemia when decoy cells are detectable. For patients with BKPyV-DNAemia loads persisting >1000 copies/mL, or exceeding 10 000 copies/mL (or equivalent), or with biopsy-proven BKPyV-nephropathy, immunosuppression should be reduced according to predefined steps targeting antiproliferative drugs, calcineurin inhibitors, or both. In adults without graft dysfunction, kidney allograft biopsy is not required unless the immunological risk is high. For children with persisting BKPyV-DNAemia, allograft biopsy may be considered even without graft dysfunction. Allograft biopsies should be interpreted in the context of all clinical and laboratory findings, including plasma BKPyV-DNAemia. Immunohistochemistry is preferred for diagnosing biopsy-proven BKPyV-nephropathy. Routine screening using the proposed strategies is cost-effective, improves clinical outcomes and quality of life. Kidney retransplantation subsequent to BKPyV-nephropathy is feasible in otherwise eligible recipients if BKPyV-DNAemia is undetectable; routine graft nephrectomy is not recommended. Current studies do not support the usage of leflunomide, cidofovir, quinolones, or IVIGs. Patients considered for experimental treatments (antivirals, vaccines, neutralizing antibodies, and adoptive T cells) should be enrolled in clinical trials.
Identifiants
pubmed: 38605438
doi: 10.1097/TP.0000000000004976
pii: 00007890-990000000-00727
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Sophie Caillard
(S)
Mario Fernandez-Ruiz
(M)
Rainer Oberbauer
(R)
Ligia Pierrotti
(L)
Cinthia Drachenberg
(C)
Yael Heher
(Y)
Gang Huang
(G)
Michael Mengel
(M)
Luis Morales Buenrostro
(L)
Brian Nankivell
(B)
Laurie Bertels
(L)
Anantharaman Vathsala
(A)
Franck Halary
(F)
Albert Heim
(A)
Deepali Kumar
(D)
Karoline Leuzinger
(K)
Christine Hanssen Rinaldo
(C)
Joanna Schaenman
(J)
Monica Slavin
(M)
Stefan Schaub
(S)
Ilies Benotmane
(I)
Nicole Theodoropoulos
(N)
Ilkka Helantera
(I)
Oliver Witzke
(O)
Steven Chadban
(S)
Soumita Bagchi
(S)
Nissreen Elfadawy
(N)
Vikas R Dharnidharka
(VR)
Motoshi Hattori
(M)
Raman Venkataramanan
(R)
Burkhard Tönshoff
(B)
Benjamin Laskin
(B)
Daniel Abramowicz
(D)
Marcelo Cantarovich
(M)
Marta Crespo
(M)
Sanjay Kumar Agarwal
(SK)
Nicolas Mueller
(N)
Ya-Chung Tian
(YC)
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
C.N.K. received grants from Biohope and funding for serving on scientific advisory boards for Roche Diagnostics. N.K. received consulting fees, honoraria, and travel support from Astellas, AstraZeneca, Biotest, CSL Behring, Chiesi, Gilead, Hansa, Merck, Sharp and Dohme, Glasgow Smith Kline, Neovii, Novartis Pharma, Roche, Sanofi, Sandoz, and Takeda. P.R. received consulting fees from Allovir. M.S. received consulting fees from Merck, Sharp and Dohme, Moderna, and Biotest and honoraria from Biotest, Novartis, Merck, Sharp and Dohme, Takeda, and Qiagen. P.C. received honoraria from Atara Bio and Pierre Fabre Pharma. H.T.S. received grants from Biohope, Merck Sharp and Dohme, Natera, Novartis, and Takeda; honoraria from Alexion, CareDx, EMS Pharmaceuticals, Natera, and Takeda; and consulting fees and travel support from Takeda. D.C.B. received grants from CareDx and VeraTherapeutics and consulting fees from CareDx, Medeor Therapeutics, Natera, Sanofi, and Vera Therapeutics. L.P. received grants from Alexion, Chiesi, and Novartis; consulting fees from Alnylam and Chiesi; and travel support from Alexion. H.H.H. received consulting fees from AICuris, Allovir, Moderna, VeraTX, and Roche and honoraria from VeraTX, Takeda, Biotest, and Gilead. The other authors declare no conflicts of interest.
Références
Wu Z, Graf FE, Hirsch HH. Antivirals against human polyomaviruses: leaving no stone unturned. Rev Med Virol. 2021;31:e2220.
Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005;79:1277–1286.
Kotton CN, Kumar D, Caliendo AM, et al.; The Transplantation Society International CMV Consensus Group. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102:900–931.
Hirsch HH, Randhawa PS; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation—guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13528.
Leuzinger K, Naegele K, Schaub S, et al. Quantification of plasma BK polyomavirus loads is affected by sequence variability, amplicon length, and non-encapsidated viral DNA genome fragments. J Clin Virol. 2019;121:104210.
Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347:488–496.
Levey AS, Eckardt KU, Dorman NM, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020;97:1117–1129.
Höcker B, Schneble L, Murer L, et al. Epidemiology of and risk factors for BK polyomavirus replication and nephropathy in pediatric renal transplant recipients: an international CERTAIN Registry study. Transplantation. 2019;103:1224–1233.
Andrews CA, Shah KV, Daniel RW, et al. A serological investigation of BK virus and JC virus infections in recipients of renal allografts. J Infect Dis. 1988;158:176–181.
Ali AM, Gibson IW, Birk P, et al. Pretransplant serologic testing to identify the risk of polyoma BK viremia in pediatric kidney transplant recipients. Pediatr Transplant. 2011;15:827–834.
Grellier J, Hirsch HH, Mengelle C, et al. Impact of donor BK polyomavirus replication on recipient infections in living donor transplantation. Transpl Infect Dis. 2018;20:e12917.
Sood P, Senanayake S, Sujeet K, et al. Donor and recipient BKV-specific IgG antibody and posttransplantation BKV infection: a prospective single-center study. Transplantation. 2013;95:896–902.
Bijol V, Cimic A, Viscidi RP, et al. Pretransplant IgG antibodies to polyoma BK virus in pediatric renal transplants. Pediatr Transplant. 2010;14:224–227.
Schwarz A, Linnenweber-Held S, Heim A, et al. Viral origin, clinical course, and renal outcomes in patients with BK virus infection after living-donor renal transplantation. Transplantation. 2016;100:844–853.
Verghese PS, Schmeling DO, Filtz EA, et al. The impact of recipient BKV shedding before transplant on BKV viruria, DNAemia, and nephropathy post-transplant: a prospective study. Pediatr Transplant. 2017;21:e12942.
Verghese PS, Schmeling DO, Knight JA, et al. The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study. Transplantation. 2015;99:602–608.
Kaur A, Wilhelm M, Wilk S, et al. BK polyomavirus-specific antibody and T-cell responses in kidney transplantation: update. Curr Opin Infect Dis. 2019;32:575–583.
Bohl DL, Brennan DC, Ryschkewitsch C, et al. BK virus antibody titers and intensity of infections after renal transplantation. J Clin Virol. 2008;43:184–189.
Wunderink HF, van der Meijden E, van der Blij-de Brouwer CS, et al. Pretransplantation donor-recipient pair seroreactivity against BK polyomavirus predicts viremia and nephropathy after kidney transplantation. Am J Transplant. 2017;17:161–172.
Solis M, Velay A, Porcher R, et al. Neutralizing antibody-mediated response and risk of BK virus-associated nephropathy. J Am Soc Nephrol. 2018;29:326–334.
Demey B, Tinez C, François C, et al. Risk factors for BK virus viremia and nephropathy after kidney transplantation: a systematic review. J Clin Virol. 2018;109:6–12.
Pourkazemi A, Shenagari M, Monfared A, et al. Analysis of risk factors influencing the BK polyomavirus replication in patients with ESRD waiting for kidney transplantation. Microb Pathog. 2020;149:104558.
Hirsch HH, Vincenti F, Friman S, et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant. 2013;13:136–145.
Ramos E, Drachenberg CB, Portocarrero M, et al. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transpl. 2002:143–153.
Cleenders E, Koshy P, Van Loon E, et al. An observational cohort study of histological screening for BK polyomavirus nephropathy following viral replication in plasma. Kidney Int. 2023;104:1018–1034.
Brochot E, Descamps V, Handala L, et al. BK polyomavirus in the urine for follow-up of kidney transplant recipients. Clin Microbiol Infect. 2019;25:112.e1–112.e5.
Dogan SE, Celebi ZK, Akturk S, et al. Prevalence and risk factors of BK viremia in patients with kidney transplantation: a single-center experience from Turkey. Transplant Proc. 2017;49:532–536.
Theodoropoulos N, Wang E, Penugonda S, et al. BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation. Am J Transplant. 2013;13:197–206.
Jacobi J, Prignitz A, Büttner M, et al. BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition. BMC Nephrol. 2013;14:207.
Shenagari M, Monfared A, Eghtedari H, et al. BK virus replication in renal transplant recipients: analysis of potential risk factors may contribute in reactivation. J Clin Virol. 2017;96:7–11.
Mitterhofer AP, Umbro I, Pietropaolo V, et al. Polyomavirus BK infection in end-stage renal disease: analysis of viral replication in patients on hemodialysis or peritoneal dialysis. Transplant Proc. 2012;44:1869–1872.
Mindlova M, Boucek P, Saudek F, et al. Prevalence and risk factors of polyomavirus BK replication in simultaneous pancreas/kidney transplant recipients from a single transplant center. Clin Transplant. 2012;26:267–274.
Maliakkal JG, Brennan DC, Goss C, et al. Ureteral stent placement and immediate graft function are associated with increased risk of BK viremia in the first year after kidney transplantation. Transpl Int. 2017;30:153–161.
Hashim F, Rehman S, Gregg JA, et al. Ureteral stent placement increases the risk for developing BK viremia after kidney transplantation. J Transplant. 2014;2014:459747.
Siparsky NF, Kushnir LF, Gallichio MH, et al. Ureteral stents: a risk factor for polyomavirus BK viremia in kidney transplant recipients undergoing protocol screening. Transplant Proc. 2011;43:2641–2644.
Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005;5:582–594.
Wingate JT, Brandenberger J, Weiss A, et al. Ureteral stent duration and the risk of BK polyomavirus viremia or bacteriuria after kidney transplantation. Transpl Infect Dis. 2017;19:e12644.
Thomas A, Dropulic LK, Rahman MH, et al. Ureteral stents: a novel risk factor for polyomavirus nephropathy. Transplantation. 2007;84:433–436.
Masutani K, Ninomiya T, Randhawa P. HLA-A2, HLA-B44 and HLA-DR15 are associated with lower risk of BK viremia. Nephrol Dial Transplant. 2013;28:3119–3126.
Kavuzlu M, Baştürk B, Ataç FB, et al. Investigation of the relationship between BK virus and human leukocyte antigens in kidney transplant recipients. Exp Clin Transplant. 2020;18(Suppl 1):51–54.
Gheith O, Al-Otaibi T, Zakaria Z, et al. Human leukocyte antigen Cw7-mediated protection against polyoma BK virus in renal transplant recipients who received grafts from antigen-positive donors. Exp Clin Transplant. 2015;13(Suppl 1):383–387.
Wunderink HF, De Brouwer CS, Gard L, et al. Source and relevance of the BK polyomavirus genotype for infection after kidney transplantation. Open Forum Infect Dis. 2019;6:ofz078.
Willhelm M, Wilk S, Kaur A, et al. Can HLA-B51 protect against BKPyV-DNAemia? Transplantation. 2019;103:e384–e385.
Leboeuf C, Wilk S, Achermann R, et al.; Swiss Transplant Cohort Study. BK polyomavirus-specific 9mer CD8 T cell responses correlate with clearance of BK viremia in kidney transplant recipients: first report from the Swiss Transplant Cohort Study. Am J Transplant. 2017;17:2591–2600.
Rohn H, Michita RT, Schramm S, et al. HLA-E polymorphism determines susceptibility to BK virus nephropathy after living-donor kidney transplant. Cells. 2019;8:847.
Vu D, Sakharkar P, Shah T, et al. Association of interferon gamma gene polymorphisms with BK virus infection among Hispanic renal allograft recipients. Transplantation. 2014;97:660–667.
Awadalla Y, Randhawa P, Ruppert K, et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant. 2004;4:1691–1696.
Borni-Duval C, Caillard S, Olagne J, et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring. Transplantation. 2013;95:1498–1505.
El-Husseini A, Hassan W, Yaseen M, et al. Impact of human leukocyte antigen and calculated panel reactive antibody on BK viremia in kidney transplant recipients: a single-center experience and literature review. Transpl Infect Dis. 2019;21:e13071.
Favi E, Puliatti C, Sivaprakasam R, et al. Incidence, risk factors, and outcome of BK polyomavirus infection after kidney transplantation. World J Clin Cases. 2019;7:270–290.
Hässig A, Roos M, Etter A, et al. Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor. Transpl Infect Dis. 2014;16:44–54.
Schold JD, Rehman S, Kayle LK, et al. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int. 2009;22:626–634.
Thangaraju S, Gill J, Wright A, et al. Risk factors for BK polyoma virus treatment and association of treatment with kidney transplant failure: insights from a paired kidney analysis. Transplantation. 2016;100:854–861.
Benavides CA, Pollard VB, Mauiyyedi S, et al. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation. 2007;84:83–88.
Dadhania D, Snopkowski C, Ding R, et al. Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication. Transplantation. 2008;86:521–528.
Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation. 2009;87:1019–1026.
Kim SJ, Rhu J, Yoo H, et al. Outcome comparison between low-dose rabbit anti-thymocyte globulin and basiliximab in low-risk living donor kidney transplantation. J Clin Med. 2020;9:1320.
Prince O, Savic S, Dickenmann M, et al. Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant. 2009;24:1024–1033.
Barbosa D, Kahwaji J, Puliyanda D, et al. Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIG and rituximab. Transplantation. 2014;97:755–761.
Hasegawa M, Ito T, Saigo K, et al. Association of DNA amplification with progress of BK polyomavirus infection and nephropathy in renal transplant recipients. Transplant Proc. 2014;46:556–559.
Hirsch HH, Randhawa P; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):179–188.
Huang G, Zhang L, Liang X, et al. Risk factors for BK virus infection and BK virus-associated nephropathy under the impact of intensive monitoring and pre-emptive immunosuppression reduction. Transplant Proc. 2014;46:3448–3454.
Mengel M, Marwedel M, Radermacher J, et al. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant. 2003;18:1190–1196.
Manitpisitkul W, Drachenberg C, Ramos E, et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. Transplantation. 2009;88:83–88.
Cosio FG, Amer H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation. 2007;83:411–416.
Schachtner T, Stein M, Babel N, et al. The loss of BKV-specific immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication. Am J Transplant. 2015;15:2159–2169.
Sood P, Senanayake S, Sujeet K, et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. Transplantation. 2012;94:814–821.
Binet I, Nickeleit V, Hirsch HH, et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation. 1999;67:918–922.
Doberer K, Schiemann M, Strassl R, et al. Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients—a prospective observational trial. Am J Transplant. 2020;20:2081–2090.
Fernández-Ruiz M, Albert E, Giménez E, et al. Early kinetics of Torque teno virus DNA load and BK polyomavirus viremia after kidney transplantation. Transpl Infect Dis. 2020;22:e13240.
Avery RK, Motter JD, Jackson KR, et al. Quantifying infection risks in incompatible living donor kidney transplant recipients. Am J Transplant. 2021;21:1564–1575.
Sharif A, Alachkar N, Bagnasco S, et al. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol. 2012;7:1320–1327.
Bentall A, Neil D, Sharif A, et al. ABO-incompatible kidney transplantation is a novel risk factor for BK nephropathy. Transplantation. 2015;99:e8–e9.
Kauke T, Klimaschewski S, Schoenermarck U, et al. Outcome after desensitization in HLA or ABO-incompatible kidney transplant recipients: a single center experience. PLoS One. 2016;11:e0146075.
Speer C, Kälble F, Nusshag C, et al. Outcomes and complications following ABO-incompatible kidney transplantation performed after desensitization by semi-selective immunoadsorption—a retrospective study. Transpl Int. 2019;32:1286–1296.
Rodríguez-Goncer I, Ruiz-Ruigómez M, López-Medrano F, et al. CMV infection, valganciclovir exposure, and the risk of BK viremia and associated nephropathy after kidney transplantation: is there a link? Transpl Infect Dis. 2021;23:e13597.
Blazquez-Navarro A, Dang-Heine C, Wittenbrink N, et al. BKV, CMV, and EBV interactions and their effect on graft function one year post-renal transplantation: results from a large multi-centre study. EBioMedicine. 2018;34:113–121.
Elfadawy N, Flechner SM, Liu X, et al. CMV viremia is associated with a decreased incidence of BKV reactivation after kidney and kidney-pancreas transplantation. Transplantation. 2013;96:1097–1103.
Toyoda M, Puliyanda DP, Amet N, et al. Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients. Transplantation. 2005;80:198–205.
Reischig T, Kacer M, Hes O, et al. Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy. Am J Transplant. 2019;19:2457–2467.
Dharnidharka VR, Cherikh WS, Neff R, et al. Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. Am J Transplant. 2010;10:1312–1315.
Geetha D, Sozio SM, Ghanta M, et al. Results of repeat renal transplantation after graft loss from BK virus nephropathy. Transplantation. 2011;92:781–786.
Hirsch HH, Ramos E. Retransplantation after polyomavirus-associated nephropathy: just do it? Am J Transplant. 2006;6:7–9.
Leeaphorn N, Thongprayoon C, Chon WJ, et al. Outcomes of kidney retransplantation after graft loss as a result of BK virus nephropathy in the era of newer immunosuppressant agents. Am J Transplant. 2020;20:1334–1340.
Muñoz-Gallego I, Díaz-Madridano N, Moral N, et al. Detection of BK polyomavirus genotypes to predict the development of BK polyomavirus-associated complications in kidney transplant recipients: a retrospective analysis. Transpl Infect Dis. 2021;23:e13615.
Nukuzuma S, Takasaka T, Zheng HY, et al. Subtype I BK polyomavirus strains grow more efficiently in human renal epithelial cells than subtype IV strains. J Gen Virol. 2006;87(Pt 7):1893–1901.
Varella RB, Zalona ACJ, Diaz NC, et al. BK polyomavirus genotypes Ia and Ib1 exhibit different biological properties in renal transplant recipients. Virus Res. 2018;243:65–68.
Virtanen E, Seppälä H, Helanterä I, et al. BK polyomavirus microRNA expression and sequence variation in polyomavirus-associated nephropathy. J Clin Virol. 2018;102:70–76.
Bauman Y, Nachmani D, Vitenshtein A, et al. An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host Microbe. 2011;9:93–102.
Leuenberger D, Andresen PA, Gosert R, et al. Human polyomavirus type 1 (BK virus) agnoprotein is abundantly expressed but immunologically ignored. Clin Vaccine Immunol. 2007;14:959–968.
Manzetti J, Weissbach FH, Graf FE, et al. BK polyomavirus evades innate immune sensing by disrupting the mitochondrial network and promotes mitophagy. iScience. 2020;23:101257.
Bethge T, Hachemi HA, Manzetti J, et al. Sp1 sites in the noncoding control region of BK polyomavirus are key regulators of bidirectional viral early and late gene expression. J Virol. 2015;89:3396–3411.
Gosert R, Rinaldo CH, Funk GA, et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med. 2008;205:841–852.
Perets TT, Silberstein I, Rubinov J, et al. High frequency and diversity of rearrangements in polyomavirus BK noncoding regulatory regions cloned from urine and plasma of Israeli renal transplant patients and evidence for a new genetic subtype. J Clin Microbiol. 2009;47:1402–1411.
Boldorini R, Allegrini S, Miglio U, et al. Genomic mutations of viral protein 1 and BK virus nephropathy in kidney transplant recipients. J Med Virol. 2009;81:1385–1393.
Sharma PM, Gupta G, Vats A, et al. Polyomavirus BK non-coding control region rearrangements in health and disease. J Med Virol. 2007;79:1199–1207.
McIlroy D, Hönemann M, Nguyen NK, et al. Persistent BK polyomavirus viruria is associated with accumulation of VP1 mutations and neutralization escape. Viruses. 2020;12:824.
Purighalla R, Shapiro R, McCauley J, et al. BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis. 1995;26:671–673.
Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation. 1999;67:103–109.
Hirsch HH. Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant. 2002;2:25–30.
Drachenberg CB, Papadimitriou JC, Hirsch HH, et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant. 2004;4:2082–2092.
Drachenberg CB, Hirsch HH, Papadimitriou JC, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation. 2007;84:323–330.
Menter T, Mayr M, Schaub S, et al. Pathology of resolving polyomavirus-associated nephropathy. Am J Transplant. 2013;13:1474–1483.
Drachenberg CB, Papadimitriou JC, Chaudhry MR, et al. Histological evolution of BK virus-associated nephropathy: importance of integrating clinical and pathological findings. Am J Transplant. 2017;17:2078–2091.
Kable K, Davies CD, O’Connell PJ, et al. Clearance of BK virus nephropathy by combination antiviral therapy with intravenous immunoglobulin. Transplant Direct. 2017;3:e142.
Drachenberg CB, Beskow CO, Cangro CB, et al. Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology. Hum Pathol. 1999;30:970–977.
Meehan SM, Kraus MD, Kadambi PV, et al. Nephron segment localization of polyoma virus large T antigen in renal allografts. Hum Pathol. 2006;37:1400–1406.
Drachenberg RC, Drachenberg CB, Papadimitriou JC, et al. Morphological spectrum of polyoma virus disease in renal allografts: diagnostic accuracy of urine cytology. Am J Transplant. 2001;1:373–381.
Wadei HM, Rule AD, Lewin M, et al. Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant. 2006;6(5 Pt 1):1025–1032.
Masutani K, Shapiro R, Basu A, et al. The Banff 2009 Working Proposal for polyomavirus nephropathy: a critical evaluation of its utility as a determinant of clinical outcome. Am J Transplant. 2012;12:907–918.
Nickeleit V, Singh HK, Randhawa P, et al.; Banff Working Group on Polyomavirus Nephropathy. The Banff Working Group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations. J Am Soc Nephrol. 2018;29:680–693.
Kowalewska J, El Moudden I, Perkowska-Ptasinska A, et al. Assessment of the Banff Working Group classification of definitive BK polyomavirus nephropathy. Transpl Int. 2021;34:2286–2296.
Bouatou Y, Nguyen TQ, Roelofs J, et al. A multicenter application of the 2018 Banff Classification for BK polyomavirus-associated nephropathy in renal transplantation. Transplantation. 2019;103:2692–2700.
Nickeleit V, Singh HK, Dadhania D, et al. The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: a multicenter validation study in the modern era. Am J Transplant. 2021;21:669–680.
Wang M, Zhou Q, Wang H, et al. An application of the 2018 Banff Classification for BK polyomavirus-associated nephropathy in renal transplantation. Transpl Infect Dis. 2021;23:e13557.
Howell DN, Smith SR, Butterly DW, et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation. 1999;68:1279–1288.
Nickeleit V, Hirsch HH, Binet IF, et al. Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. J Am Soc Nephrol. 1999;10:1080–1089.
Jeong HJ, Hong SW, Sung SH, et al. Polyomavirus nephropathy in renal transplantation: a clinico-pathological study. Transpl Int. 2003;16:671–675.
Celik B, Randhawa PS. Glomerular changes in BK virus nephropathy. Hum Pathol. 2004;35:367–370.
Chen XT, Deng RH, Yang SC, et al. Pathological characteristics of BK polyomavirus-associated nephropathy with glomerular involvement. Ann Transl Med. 2020;8:923.
Brealey JK. Ultrastructural observations in a case of BK virus nephropathy with viruses in glomerular subepithelial humps. Ultrastruct Pathol. 2007;31:1–7.
Ravindran A, Kashtan CE, Sethi S. BK nephropathy with glomerular involvement. Kidney Int. 2018;94:432.
Nankivell BJ, Renthawa J, Shingde M, et al. The importance of kidney medullary tissue for the accurate diagnosis of BK virus allograft nephropathy. Clin J Am Soc Nephrol. 2020;15:1015–1023.
Nankivell BJ, Renthawa J, Sharma RN, et al. BK virus nephropathy: histological evolution by sequential pathology. Am J Transplant. 2017;17:2065–2077.
Batal I, Franco ZM, Shapiro R, et al. Clinicopathologic analysis of patients with BK viruria and rejection-like graft dysfunction. Hum Pathol. 2009;40:1312–1319.
Masutani K, Shapiro R, Basu A, et al. Putative episodes of T-cell-mediated rejection in patients with sustained BK viruria but no viremia. Transplantation. 2012;94:43–49.
Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020;20:2318–2331.
Womer KL, Guerra G, Dibadj K, et al. Immunosuppression reduction for BK virus nephropathy: a case for caution. Transpl Infect Dis. 2007;9:244–248.
Atsumi H, Asaka M, Kimura S, et al. A case of second renal transplantation with acute antibody-mediated rejection complicated with BK virus nephropathy. Clin Transplant. 2010;24(Suppl 22):35–38.
Mainra R, Xu Q, Chibbar R, et al. Severe antibody-mediated rejection following IVIG infusion in a kidney transplant recipient with BK-virus nephropathy. Transpl Immunol. 2013;28:145–147.
Batal I, Zainah H, Stockhausen S, et al. The significance of renal C4d staining in patients with BK viruria, viremia, and nephropathy. Mod Pathol. 2009;22:1468–1476.
Mohamed M, Parajuli S, Muth B, et al. In kidney transplant recipients with BK polyomavirus infection, early BK nephropathy, microvascular inflammation, and serum creatinine are risk factors for graft loss. Transpl Infect Dis. 2016;18:361–371.
Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant. 2000;15:324–332.
Schaub S, Mayr M, Egli A, et al. Transient allograft dysfunction from immune reconstitution in a patient with polyoma BK-virus-associated nephropathy. Nephrol Dial Transplant. 2007;22:2386–2390.
Dziubianau M, Hecht J, Kuchenbecker L, et al. TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology. Am J Transplant. 2013;13:2842–2854.
Zeng G, Huang Y, Huang Y, et al. Antigen-specificity of T cell infiltrates in biopsies with T cell-mediated rejection and BK polyomavirus viremia: analysis by next generation sequencing. Am J Transplant. 2016;16:3131–3138.
Adam BA, Kikic Z, Wagner S, et al. Intragraft gene expression in native kidney BK virus nephropathy versus T cell-mediated rejection: prospects for molecular diagnosis and risk prediction. Am J Transplant. 2020;20:3486–3501.
Meehan SM, Kadambi PV, Manaligod JR, et al. Polyoma virus infection of renal allografts: relationships of the distribution of viral infection, tubulointerstitial inflammation, and fibrosis suggesting viral interstitial nephritis in untreated disease. Hum Pathol. 2005;36:1256–1264.
Mannon RB, Hoffmann SC, Kampen RL, et al. Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant. 2005;5:2883–2893.
Rogers NM, Russ GR, Cooper J, et al. Immunophenotyping of interstitial infiltrate does not distinguish between BK virus nephropathy and acute cellular rejection. Nephrology (Carlton). 2009;14:118–122.
Buettner M, Xu H, Böhme R, et al. Predominance of TH2 cells and plasma cells in polyoma virus nephropathy: a role for humoral immunity? Hum Pathol. 2012;43:1453–1462.
Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int. 1993;44:411–422.
McGregor SM, Chon WJ, Kim L, et al. Clinical and pathological features of kidney transplant patients with concurrent polyomavirus nephropathy and rejection-associated endarteritis. World J Transplant. 2015;5:292–299.
Wiegley N, Walavalkar V, Aujla H, et al. Clinicopathologic characteristics of JC virus nephropathy in kidney transplant recipients. Transplantation. 2021;105:1069–1076.
Lautenschlager I, Jahnukainen T, Kardas P, et al. A case of primary JC polyomavirus infection-associated nephropathy. Am J Transplant. 2014;14:2887–2892.
Höcker B, Tabatabai J, Schneble L, et al. JC polyomavirus replication and associated disease in pediatric renal transplantation: an international CERTAIN Registry study. Pediatr Nephrol. 2018;33:2343–2352.
Aguilar J, Chang DH, Lin M, et al. JC virus-associated nephropathy in a post-heart and -kidney transplantation patient. Transpl Infect Dis. 2020;22:e13288.
Asim M, Chong-Lopez A, Nickeleit V. Adenovirus infection of a renal allograft. Am J Kidney Dis. 2003;41:696–701.
Kozlowski T, Nickeleit V, Andreoni K. Donor-transmitted adenovirus infection causing kidney allograft nephritis and graft loss. Transpl Infect Dis. 2011;13:168–173.
Nanmoku K, Ishikawa N, Kurosawa A, et al. Clinical characteristics and outcomes of adenovirus infection of the urinary tract after renal transplantation. Transpl Infect Dis. 2016;18:234–239.
Hemmersbach-Miller M, Duronville J, Sethi S, et al. Hemorrhagic herpes simplex virus type 1 nephritis: an unusual cause of acute allograft dysfunction. Am J Transplant. 2017;17:287–291.
Hensley JL, Sifri CD, Cathro HP, et al. Adenoviral graft-nephritis: case report and review of the literature. Transpl Int. 2009;22:672–677.
Lee Y, Kim YJ, Cho H. BK virus nephropathy and multiorgan involvement in a child with heart transplantation. Clin Nephrol. 2019;91:107–113.
Adam B, Randhawa P, Chan S, et al. Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): reproducibility of polyomavirus immunohistochemistry in kidney allografts. Am J Transplant. 2014;14:2137–2147.
Pan L, Lyu Z, Adam B, et al. Polyomavirus BK nephropathy-associated transcriptomic signatures: a critical reevaluation. Transplant Direct. 2018;4:e339.
Halloran PF, Madill-Thomsen KS, Böhmig GA, et al.; INTERCOMEX Investigators. A 2-fold approach to polyoma virus (BK) nephropathy in kidney transplants: distinguishing direct virus effects from cognate T cell-mediated inflammation. Transplantation. 2021;105:2374–2384.
Ramos E, Drachenberg CB, Wali R, et al. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation. 2009;87:621–630.
Egli A, Dumoulin A, Köhli S, et al. Polyomavirus BK after kidney transplantation—role of molecular and immunological markers. Trends Transpl. 2009;3:85–102.
Ahlenstiel-Grunow T, Sester M, Sester U, et al. BK polyomavirus-specific T cells as a diagnostic and prognostic marker for BK polyomavirus infections after pediatric kidney transplantation. Transplantation. 2020;104:2393–2402.
David-Neto E, Agena F, Silva Ribeiro David D, et al. Effect of polyoma viremia on 3-year allograft kidney function. Transpl Infect Dis. 2019;21:e13056.
Imlay H, Whitaker K, Fisher CE, et al. Clinical characteristics and outcomes of late-onset BK virus nephropathy in kidney and kidney-pancreas transplant recipients. Transpl Infect Dis. 2018;20:e12928.
Bischof N, Hirsch HH, Wehmeier C, et al. Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long-term outcomes. Nephrol Dial Transplant. 2019;34:1240–1250.
Randhawa P, Ho A, Shapiro R, et al. Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients. J Clin Microbiol. 2004;42:1176–1180.
Funk GA, Gosert R, Comoli P, et al. Polyomavirus BK replication dynamics in vivo and in silico to predict cytopathology and viral clearance in kidney transplants. Am J Transplant. 2008;8:2368–2377.
Kim GJ, Lee JH, Lee DH. Clinical and prognostic significance of Merkel cell polyomavirus in nonsmall cell lung cancer. Medicine (Baltimore). 2017;96:e5413.
Ramanan P, Timmerman EA, Fidler ME, et al. A kidney transplant recipient with renal medullary viral cytopathic changes. Transpl Infect Dis. 2017;19:e12646.
Schaub S, Hirsch HH, Dickenmann M, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant. 2010;10:2615–2623.
Hassan S, Mittal C, Amer S, et al. Currently recommended BK virus (BKV) plasma viral load cutoff of ≥4 log10/mL underestimates the diagnosis of BKV-associated nephropathy: a single transplant center experience. Transpl Infect Dis. 2014;16:55–60.
Agrawal N, Echenique IA, Meehan SM, et al. Variability in assessing for BK viremia: whole blood is not reliable and plasma is not above reproach—a retrospective analysis. Transpl Int. 2017;30:670–678.
Leuzinger K, Hirsch HH. Human polyomaviruses. Man Clin Microbiol. 2023;2:2093–2130.
Kudose S, Dong J. Clinical validation study of quantitative real-time PCR assay for detection and monitoring of BK virus nephropathy. Ann Clin Lab Sci. 2014;44:455–460.
Bicalho CS, Oliveira RDR, David DR, et al. Determination of viremia cut-off for risk to develop BKPyV-associated nephropathy among kidney transplant recipients. Transpl Infect Dis. 2018;20:e12969.
Costa C, Bergallo M, Astegiano S, et al. Monitoring of BK virus replication in the first year following renal transplantation. Nephrol Dial Transplant. 2008;23:3333–3336.
Dumoulin A, Hirsch HH. Reevaluating and optimizing polyomavirus BK and JC real-time PCR assays to detect rare sequence polymorphisms. J Clin Microbiol. 2011;49:1382–1388.
Hoffman NG, Cook L, Atienza EE, et al. Marked variability of BK virus load measurement using quantitative real-time PCR among commonly used assays. J Clin Microbiol. 2008;46:2671–2680.
Solis M, Meddeb M, Sueur C, et al.; French BKV Study Group. Sequence variation in amplification target genes and standards influences interlaboratory comparison of BK virus DNA load measurement. J Clin Microbiol. 2015;53:3842–3852.
Randhawa PS, Khaleel-Ur-Rehman K, Swalsky PA, et al. DNA sequencing of viral capsid protein VP-1 region in patients with BK virus interstitial nephritis. Transplantation. 2002;73:1090–1094.
Leuzinger K, Kaur A, Wilhelm M, et al. Molecular characterization of BK polyomavirus replication in allogeneic hematopoietic cell transplantation patients. J Infect Dis. 2023;227:888–900.
Hasan MR, Tan R, Al-Rawahi G, et al. Comparative evaluation of laboratory developed real-time PCR assays and RealStar(®) BKV PCR kit for quantitative detection of BK polyomavirus. J Virol Methods. 2016;234:80–86.
Bateman AC, Greninger AL, Atienza EE, et al. Quantification of BK virus standards by quantitative real-time PCR and droplet digital PCR is confounded by multiple virus populations in the WHO BKV international standard. Clin Chem. 2017;63:761–769.
Jin L. Molecular methods for identification and genotyping of BK virus. Methods Mol Biol. 2001;165:33–48.
Torres C. Evolution and molecular epidemiology of polyomaviruses. Infect Genet Evol. 2020;79:104150.
Luo C, Bueno M, Kant J, et al. Genotyping schemes for polyomavirus BK, using gene-specific phylogenetic trees and single nucleotide polymorphism analysis. J Virol. 2009;83:2285–2297.
Leuzinger K, Kaur A, Wilhelm M, et al. Variations in BK polyomavirus immunodominant large tumor antigen-specific 9mer CD8 T-cell epitopes predict altered HLA-presentation and immune failure. Viruses. 2020;12:1476.
Bodaghi S, Comoli P, Bösch R, et al. Antibody responses to recombinant polyomavirus BK large T and VP1 proteins in young kidney transplant patients. J Clin Microbiol. 2009;47:2577–2585.
Kardas P, Leboeuf C, Hirsch HH. Optimizing JC and BK polyomavirus IgG testing for seroepidemiology and patient counseling. J Clin Virol. 2015;71:28–33.
Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol. 2003;71:115–123.
Kean JM, Rao S, Wang M, et al. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5:e1000363.
Schmidt T, Adam C, Hirsch HH, et al. BK polyomavirus-specific cellular immune responses are age-dependent and strongly correlate with phases of virus replication. Am J Transplant. 2014;14:1334–1345.
Abend JR, Changala M, Sathe A, et al. Correlation of BK virus neutralizing serostatus with the incidence of BK viremia in kidney transplant recipients. Transplantation. 2017;101:1495–1505.
Bohl DL, Storch GA, Ryschkewitsch C, et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant. 2005;5:2213–2221.
Smith JM, McDonald RA, Finn LS, et al. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant. 2004;4:2109–2117.
Hariharan S, Cohen EP, Vasudev B, et al. BK virus-specific antibodies and BKV DNA in renal transplant recipients with BKV nephritis. Am J Transplant. 2005;5:2719–2724.
Randhawa PS, Gupta G, Vats A, et al. Immunoglobulin G, A, and M responses to BK virus in renal transplantation. Clin Vaccine Immunol. 2006;13:1057–1063.
Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant. 2007;7:2727–2735.
Randhawa P, Zemlicka J, Sauerbrei A, et al. Anti-BK virus activity of nucleoside analogs. Antimicrob Agents Chemother. 2008;52:1519–1521.
Wunderink HF, van der Meijden E, van der Blij-de Brouwer CS, et al. Stability of BK polyomavirus IgG seroreactivity and its correlation with preceding viremia. J Clin Virol. 2017;90:46–51.
Lorentzen EM, Henriksen S, Kaur A, et al. Early fulminant BK polyomavirus-associated nephropathy in two kidney transplant patients with low neutralizing antibody titers receiving allografts from the same donor. Virol J. 2020;17:5.
Hammer MH, Brestrich G, Andree H, et al. HLA type-independent method to monitor polyoma BK virus-specific CD4 and CD8 T-cell immunity. Am J Transplant. 2006;6:625–631.
Sester M, Leboeuf C, Schmidt T, et al. The “ABC” of virus-specific T cell immunity in solid organ transplantation. Am J Transplant. 2016;16:1697–1706.
Binggeli S, Egli A, Schaub S, et al. Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant. 2007;7:1131–1139.
Wilhelm M, Kaur A, Wernli M, et al. BK polyomavirus-specific CD8 T-cell expansion in vitro using 27mer peptide antigens for developing adoptive T-cell transfer and vaccination. J Infect Dis. 2021;223:1410–1422.
Krymskaya L, Sharma MC, Martinez J, et al. Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. J Virol. 2005;79:11170–11178.
Chen Y, Trofe J, Gordon J, et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol. 2006;80:3495–3505.
Weist BJ, Wehler P, El Ahmad L, et al. A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients. Kidney Int. 2015;88:1293–1303.
Cioni M, Leboeuf C, Comoli P, et al. Characterization of immunodominant BK polyomavirus 9mer epitope T cell responses. Am J Transplant. 2016;16:1193–1206.
Mutlu E, Köksoy S, Mutlu D, et al. Quantitative analysis of BKV-specific CD4+ T cells before and after kidney transplantation. Transpl Immunol. 2015;33:20–26.
DeWolfe D, Gandhi J, Mackenzie MR, et al. Pre-transplant immune factors may be associated with BK polyomavirus reactivation in kidney transplant recipients. PLoS One. 2017;12:e0177339.
Lepore M, Crespo E, Melilli E, et al. Functional immune monitoring of BK virus and donor-specific T-cell effector immune responses to guide treatment decision-making after kidney transplantation; an illustrative case report and literature review. Transpl Infect Dis. 2021;23:e13495.
Udomkarnjananun S, Kerr SJ, Francke MI, et al. A systematic review and meta-analysis of enzyme-linked immunosorbent spot (ELISpot) assay for BK polyomavirus immune response monitoring after kidney transplantation. J Clin Virol. 2021;140:104848.
Egli A, Köhli S, Dickenmann M, et al. Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs. Transplantation. 2009;88:1161–1168.
Schachtner T, Müller K, Stein M, et al. BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant. 2011;11:2443–2452.
Trydzenskaya H, Sattler A, Müller K, et al. Novel approach for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immunity. Transplantation. 2011;92:1269–1277.
Schaenman JM, Korin Y, Sidwell T, et al. Increased frequency of BK virus-specific polyfunctional CD8+ T cells predict successful control of BK viremia after kidney transplantation. Transplantation. 2017;101:1479–1487.
Ahlenstiel-Grunow T, Pape L. Immunosuppression, BK polyomavirus infections, and BK polyomavirus-specific T cells after pediatric kidney transplantation. Pediatr Nephrol. 2020;35:625–631.
van Aalderen MC, Remmerswaal EB, Heutinck KM, et al. Clinically relevant reactivation of polyomavirus BK (BKPyV) in HLA-A02-positive renal transplant recipients is associated with impaired effector-memory differentiation of BKPyV-specific CD8+ T cells. PLoS Pathog. 2016;12:e1005903.
Sigdel TK, Vitalone MJ, Tran TQ, et al. A rapid noninvasive assay for the detection of renal transplant injury. Transplantation. 2013;96:97–101.
Beck J, Bierau S, Balzer S, et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem. 2013;59:1732–1741.
Chen XT, Chen WF, Hou XT, et al. Non-invasive urinary sediment double-immunostaining predicts BK polyomavirus associated-nephropathy in kidney transplant recipients. Ann Transl Med. 2020;8:235.
Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant. 2011;11:2228–2234.
Hu H, Aizenstein BD, Puchalski A, et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant. 2004;4:432–437.
Willhelm M, Wilk S, Kaur A, et al.; Swiss Transplant Cohort Study. Can HLA-B51 protect against BKPyV-DNAemia? Transplantation. 2019;103:e384–e385.
Burek Kamenaric M, Ivkovic V, Kovacevic Vojtusek I, et al. The role of HLA and KIR immunogenetics in BK virus infection after kidney transplantation. Viruses. 2020;12:1417.
Azar MM, Assi R, Valika AK, et al. Graft loss among renal-transplant recipients with early reduction of immunosuppression for BK viremia. World J Transplant. 2017;7:269–275.
Sharma R, Zachariah M. BK virus nephropathy: prevalence, impact and management strategies. Int J Nephrol Renovasc Dis. 2020;13:187–192.
Reischig T, Kacer M, Hes O, et al. Viral load and duration of BK polyomavirus viraemia determine renal graft fibrosis progression: histologic evaluation of late protocol biopsies. Nephrol Dial Transplant. 2019;34:1970–1978.
Lee S, Lee KW, Kim SJ, et al. Clinical characteristic and outcomes of BK virus infection in kidney transplant recipients managed using a systematic surveillance and treatment strategy. Transplant Proc. 2020;52:1749–1756.
McGann K, DeWolfe D, Jacobs M, et al. Comparing urine and blood screening methods to detect BK virus after renal transplant. Exp Clin Transplant. 2021;19:104–109.
Schachtner T, Zaks M, Kahl A, et al. Simultaneous pancreas/kidney transplant recipients present with late-onset BK polyomavirus-associated nephropathy. Nephrol Dial Transplant. 2016;31:1174–1182.
Serrano OK, Kutzler HL, Rochon C, et al. Incidental COVID-19 in a heart-kidney transplant recipient with malnutrition and recurrent infections: implications for the SARS-CoV-2 immune response. Transpl Infect Dis. 2020;22:e13367.
Ujire MP, Curry MP, Stillman IE, et al. A simultaneous liver-kidney transplant recipient with IgA nephropathy limited to native kidneys and BK virus nephropathy limited to the transplant kidney. Am J Kidney Dis. 2013;62:331–334.
Puliyanda DP, Amet N, Dhawan A, et al. Isolated heart and liver transplant recipients are at low risk for polyomavirus BKV nephropathy. Clin Transplant. 2006;20:289–294.
Razonable RR, Brown RA, Humar A, et al.; PV16000 Study Group. A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis. 2005;192:1349–1354.
Viswesh V, Yost SE, Kaplan B. The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: a systematic review. Transplant Rev (Orlando). 2015;29:175–180.
Egli A, Helmersen DS, Taub K, et al. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. Am J Transplant. 2010;10:2324–2330.
Mallavarapu RK, Sanoff SL, Howell DN, et al. BK virus nephropathy in non-renal solid organ transplant recipients: are we looking hard enough? Clin Transplant. 2021;35:e14265.
Loeches B, Valerio M, Palomo J, et al. BK virus in heart transplant recipients: a prospective study. J Heart Lung Transplant. 2011;30:109–111.
Loeches B, Valerio M, Pérez M, et al.; BKV Study Group of the Gregorio Marañón Hospital. BK virus in liver transplant recipients: a prospective study. Transplant Proc. 2009;41:1033–1037.
Munker D, Veit T, Schönermarck U, et al. Polyomavirus exerts detrimental effects on renal function in patients after lung transplantation. J Clin Virol. 2021;145:105029.
Barton TD, Blumberg EA, Doyle A, et al. A prospective cross-sectional study of BK virus infection in non-renal solid organ transplant recipients with chronic renal dysfunction. Transpl Infect Dis. 2006;8:102–107.
Herrmann A, Sandmann L, Adams O, et al. Role of BK polyomavirus (BKV) and Torque teno virus (TTV) in liver transplant recipients with renal impairment. J Med Microbiol. 2018;67:1496–1508.
Yetmar ZA, Kudva YC, Seville MT, et al. BK polyomavirus DNAemia in pancreas transplant recipients compared to pancreas-kidney recipients. Clin Transplant. 2023;37:e15135.
Chikeka IO, Paulk A, Haririan A, et al. Concurrent cytomegalovirus glomerulitis and BK polyomavirus-associated nephropathy in a kidney allograft biopsy. Transpl Infect Dis. 2016;18:247–250.
Kenan DJ, Mieczkowski PA, Burger-Calderon R, et al. The oncogenic potential of BK-polyomavirus is linked to viral integration into the human genome. J Pathol. 2015;237:379–389.
Müller DC, Rämö M, Naegele K, et al. Donor-derived, metastatic urothelial cancer after kidney transplantation associated with a potentially oncogenic BK polyomavirus. J Pathol. 2018;244:265–270.
Cotiguala L, Masood A, Park JM, et al. Increasing net immunosuppression after BK polyoma virus infection. Transpl Infect Dis. 2021;23:e13472.
Querido S, Fernandes I, Weigert A, et al. High-grade urothelial carcinoma in a kidney transplant recipient after JC virus nephropathy: the first evidence of JC virus as a potential oncovirus in bladder cancer. Am J Transplant. 2020;20:1188–1191.
Gupta G, Kuppachi S, Kalil RS, et al. Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States. Am J Transplant. 2018;18:245–252.
Johnston O, Jaswal D, Gill JS, et al. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation. 2010;89:1057–1070.
Hardinger KL, Koch MJ, Bohl DJ, et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant. 2010;10:407–415.
Devresse A, Tinel C, Vermorel A, et al. No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained BK virus viremia after kidney transplantation: a single-center experience. Transpl Int. 2019;32:481–492.
Alméras C, Foulongne V, Garrigue V, et al. Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation. 2008;85:1099–1104.
Saad ER, Bresnahan BA, Cohen EP, et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation. 2008;85:850–854.
Seifert ME, Gunasekaran M, Horwedel TA, et al. Polyomavirus reactivation and immune responses to kidney-specific self-antigens in transplantation. J Am Soc Nephrol. 2017;28:1314–1325.
Sawinski D, Forde KA, Trofe-Clark J, et al. Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies. J Am Soc Nephrol. 2015;26:966–975.
Cheungpasitporn W, Kremers WK, Lorenz E, et al. De novo donor-specific antibody following BK nephropathy: the incidence and association with antibody-mediated rejection. Clin Transplant. 2018;32:e13194.
Leuzinger K, Hirsch HH. Human polyomaviruses. In: Carroll KC, Pfaller MA, eds. Manual of Clinical Microbiology. Vol 2. 12th ed; ASM Press; 2023.
Kharel A, Djamali A, Jorgenson MR, et al. Risk factors for progression from low level BK DNAemia to unfavorable outcomes after BK management via immunosuppressive reduction. Transpl Infect Dis. 2021;23:e13561.
Steubl D, Baumann M, Schuster T, et al. Risk factors and interventional strategies for BK polyomavirus infection after renal transplantation. Scand J Urol Nephrol. 2012;46:466–474.
Kantauskaite M, Muller L, Kolb T, et al. Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients. Am J Transplant. 2022;22:634–639.
Meziyerh S, Bouwmans P, van Gelder T, et al.; RECOVAC Collaborators. Mycophenolic acid exposure determines antibody formation following SARS-CoV-2 vaccination in kidney transplant recipients: a nested cohort study. Clin Pharmacol Ther. 2023;114:118–126.
Baek CH, Kim H, Yu H, et al. Risk factors of acute rejection in patients with BK nephropathy after reduction of immunosuppression. Ann Transplant. 2018;23:704–712.
Kant S, Bromberg J, Haas M, et al. Donor-derived cell-free DNA and the prediction of BK virus-associated nephropathy. Transplant Direct. 2020;6:e622.
Bestard O, Augustine J, Wee A, et al. Prospective observational study to validate a next-generation sequencing blood RNA signature to predict early kidney transplant rejection. Am J Transplant. 2024;24:436–447.
Tedesco-Silva H, Pascual J, Viklicky O, et al.; TRANSFORM Investigators. Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study. Transplantation. 2019;103:1953–1963.
Sommerer C, Suwelack B, Dragun D, et al.; Athena Study Group. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int. 2019;96:231–244.
Wojciechowski D, Chandran S, Webber A, et al. Mycophenolate mofetil withdrawal with conversion to everolimus to treat BK virus infection in kidney transplant recipients. Transplant Proc. 2017;49:1773–1778.
Bussalino E, Marsano L, Parodi A, et al. Everolimus for BKV nephropathy in kidney transplant recipients: a prospective, controlled study. J Nephrol. 2021;34:531–538.
Belliere J, Kamar N, Mengelle C, et al. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia. Transpl Int. 2016;29:315–322.
Adams AB, Goldstein J, Garrett C, et al. Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function. Am J Transplant. 2017;17:2922–2936.
Karadkhele G, Hogan J, Magua W, et al. CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept. Am J Transplant. 2021;21:208–221.
Westphal SG, Lyden ER, Langewisch ED, et al. BK viremia surveillance and outcomes in simultaneous pancreas-kidney transplant recipients. Clin Transplant. 2017;31:e13010.
Mujtaba M, Fridell J, Sharfuddin A, et al. BK virus nephropathy in simultaneous pancreas kidney transplant: a potentially preventable cause of kidney allograft loss. Clin Transplant. 2012;26:E87–E93.
Akpinar E, Ciancio G, Sageshima J, et al. BK virus nephropathy after simultaneous pancreas-kidney transplantation. Clin Transplant. 2010;24:801–806.
Gupta G, Shapiro R, Thai N, et al. Low incidence of BK virus nephropathy after simultaneous kidney pancreas transplantation. Transplantation. 2006;82:382–388.
Kuten SA, Patel SJ, Knight RJ, et al. Observations on the use of cidofovir for BK virus infection in renal transplantation. Transpl Infect Dis. 2014;16:975–983.
Velay A, Solis M, Benotmane I, et al. Intravenous immunoglobulin administration significantly increases BKPyV genotype-specific neutralizing antibody titers in kidney transplant recipients. Antimicrob Agents Chemother. 2019;63:e00393–e00319.
Randhawa P, Pastrana DV, Zeng G, et al. Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK. Am J Transplant. 2015;15:1014–1020.
Benotmane I, Solis M, Velay A, et al. Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipients—results from a proof-of-concept study. Am J Transplant. 2021;21:329–337.
Moon J, Chang Y, Shah T, et al. Effects of intravenous immunoglobulin therapy and Fc gamma receptor polymorphisms on BK virus nephropathy in kidney transplant recipients. Transpl Infect Dis. 2020;22:e13300.
Nesselhauf N, Strutt J, Bastani B. Evaluation of leflunomide for the treatment of BK viremia and biopsy proven BK nephropathy; a single center experience. J Nephropathol. 2016;5:34–37.
Bernhoff E, Gutteberg TJ, Sandvik K, et al. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant. 2008;8:1413–1422.
Burgos D, López V, Cabello M, et al. Polyomavirus BK nephropathy: the effect of an early diagnosis on renal function or graft loss. Transplant Proc. 2006;38:2409–2411.
Bernhoff E, Tylden GD, Kjerpeseth LJ, et al. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J Virol. 2010;84:2150–2156.
Keller N, Duquennoy S, Conrad A, et al. Clinical utility of leflunomide for BK polyomavirus associated nephropathy in kidney transplant recipients: a multicenter retrospective study. Transpl Infect Dis. 2019;21:e13058.
Cuellar-Rodriguez J, Stephany B, Poggio E, et al. Contrasting patterns of viral load response in transplant recipients with BK polyomavirus DNAemia on leflunomide therapy. Clin Transplant. 2013;27:E230–E236.
Krisl JC, Taber DJ, Pilch N, et al. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection. Clin J Am Soc Nephrol. 2012;7:1003–1009.
Teschner S, Gerke P, Geyer M, et al. Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection. Transplant Proc. 2009;41:2533–2538.
Leca N, Muczynski KA, Jefferson JA, et al. Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. Clin J Am Soc Nephrol. 2008;3:829–835.
Faguer S, Hirsch HH, Kamar N, et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int. 2007;20:962–969.
Josephson MA, Gillen D, Javaid B, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation. 2006;81:704–710.
Guasch A, Roy-Chaudhury P, Woodle ES, et al.; FK778 BK Nephropathy Study Group. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation. 2010;90:891–897.
Yamazaki T, Shirai H, Tojimbara T. Use of leflunomide as an antiviral agent with everolimus for BK virus nephropathy patients after kidney transplantation: a case series. Am J Case Rep. 2020;21:e927367.
Gabardi S, Waikar SS, Martin S, et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol. 2010;5:1298–1304.
Wojciechowski D, Chanda R, Chandran S, et al. Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year. Transplantation. 2012;94:1117–1123.
Song TR, Rao ZS, Qiu Y, et al. Fluoroquinolone prophylaxis in preventing BK polyomavirus infection after renal transplant: a systematic review and meta-analysis. Kaohsiung J Med Sci. 2016;32:152–159.
Knoll GA, Humar A, Fergusson D, et al. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. JAMA. 2014;312:2106–2114.
Patel SJ, Knight RJ, Kuten SA, et al. Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: results of a prospective, double-blind, randomized, placebo-controlled trial. Am J Transplant. 2019;19:1831–1837.
Moriyama T, Sorokin A. Repression of BK virus infection of human renal proximal tubular epithelial cells by pravastatin. Transplantation. 2008;85:1311–1317.
Gabardi S, Ramasamy S, Kim M, et al. Impact of HMG-CoA reductase inhibitors on the incidence of polyomavirus-associated nephropathy in renal transplant recipients with human BK polyomavirus viremia. Transpl Infect Dis. 2015;17:536–543.
Ginevri F, De Santis R, Comoli P, et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation. 2003;75:1266–1270.
Bracamonte E, Leca N, Smith KD, et al. Tubular basement membrane immune deposits in association with BK polyomavirus nephropathy. Am J Transplant. 2007;7:1552–1560.
Matossian D, Langman CB, Cohn RA, et al. Obstructive uropathy is associated with polyomavirus viremia in pediatric kidney transplantation. Pediatr Transplant. 2012;16:729–734.
Harada R, Hamasaki Y, Okuda Y, et al. Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies. Pediatr Nephrol. 2022;37:1215–1229.
Smith JM, Dharnidharka VR, Talley L, et al. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol. 2007;2:1037–1042.
Ahlenstiel-Grunow T, Liu X, Schild R, et al. Steering transplant immunosuppression by measuring virus-specific T cell levels: the randomized, controlled IVIST trial. J Am Soc Nephrol. 2021;32:502–516.
Pape L, Tönshoff B, Hirsch HH; Members of the Working Group ‘Transplantation’ of the European Society for Paediatric Nephrology. Perception, diagnosis and management of BK polyomavirus replication and disease in paediatric kidney transplant recipients in Europe. Nephrol Dial Transplant. 2016;31:842–847.
Dharnidharka VR, Vyas N, Gaut JP, et al. The utility of surveillance biopsies in pediatric kidney transplantation. Pediatr Nephrol. 2018;33:889–895.
Kanzelmeyer NK, Ahlenstiel T, Drube J, et al. Protocol biopsy-driven interventions after pediatric renal transplantation. Pediatr Transplant. 2010;14:1012–1018.
Odum JD, Kats A, VanSickle JS, et al. Characterizing the frequency of modifiable histological changes observed on surveillance biopsies in pediatric kidney allograft recipients. Pediatr Nephrol. 2020;35:2173–2182.
Zaman RA, Ettenger RB, Cheam H, et al. A novel treatment regimen for BK viremia. Transplantation. 2014;97:1166–1171.
Alexander RT, Langlois V, Tellier R, et al. The prevalence of BK viremia and urinary viral shedding in a pediatric renal transplant population: a single-center retrospective analysis. Pediatr Transplant. 2006;10:586–592.
Hamasaki Y, Dolan NM, Cubitt D, et al. BK viremia and nephropathy in pediatric renal transplant recipients. Pediatr Transplant. 2019;23:e13460.
Hymes LC, Warshaw BL. Polyomavirus (BK) in pediatric renal transplants: evaluation of viremic patients with and without BK associated nephritis. Pediatr Transplant. 2006;10:920–922.
Hymes LC, Warshaw BL. Five-year experience using sirolimus-based, calcineurin inhibitor-free immunosuppression in pediatric renal transplantation. Pediatr Transplant. 2011;15:437–441.
Montini G, Murer L, Ghio L, et al. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient. Transpl Int. 2005;18:36–42.
Anyaegbu EI, Almond PS, Milligan T, et al. Intravenous immunoglobulin therapy in the treatment of BK viremia and nephropathy in pediatric renal transplant recipients. Pediatr Transplant. 2012;16:E19–E24.
Araya CE, Lew JF, Fennell RS 3rd, et al. Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy. Pediatr Transplant. 2006;10:32–37.
Al Khasawneh E, Araya CE, Dharnidharka VR. Missed viral surveillance testing visits associate with full blown viral diseases in children receiving kidney transplants. Pediatr Transplant. 2013;17:129–132.
Herman J, Van Ranst M, Snoeck R, et al. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique. Pediatr Transplant. 2004;8:485–492.
Kizilbash SJ, Rheault MN, Bangdiwala A, et al. Infection rates in tacrolimus versus cyclosporine-treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1-year analysis. Pediatr Transplant. 2017;21:e12919.
Puliyanda DP, Toyoda M, Traum AZ, et al. Outcome of management strategies for BK virus replication in pediatric renal transplant recipients. Pediatr Transplant. 2008;12:180–186.
Celik B, Shapiro R, Vats A, et al. Polyomavirus allograft nephropathy: sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression. Am J Transplant. 2003;3:1378–1382.
Zarauza Santoveña A, García Meseguer C, Martínez Mejía S, et al. BK virus infection in pediatric renal transplantation. Transplant Proc. 2015;47:62–66.
Araya CE, Garin EH, Neiberger RE, et al. Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients. Pediatr Transplant. 2010;14:145–150.
Cho YH, Hyun HS, Park E, et al. Higher incidence of BK virus nephropathy in pediatric kidney allograft recipients with Alport syndrome. J Clin Med. 2019;8:491.
Jung YH, Moon KC, Ha JW, et al. Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation. Pediatr Transplant. 2013;17:E50–E54.
Launay M, Baudouin V, Guillemain R, et al. Leflunomide for BK virus: report of seven kidney-transplanted children. Int J Organ Transplant Med. 2018;9:178–183.
Araya CE, Lew JF, Fennell RS, et al. Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. Pediatr Transplant. 2008;12:790–795.
Vats A, Shapiro R, Singh Randhawa P, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation. 2003;75:105–112.
Sharma AP, Moussa M, Casier S, et al. Intravenous immunoglobulin as rescue therapy for BK virus nephropathy. Pediatr Transplant. 2009;13:123–129.
Funk GA, Steiger J, Hirsch HH. Rapid dynamics of polyomavirus type BK in renal transplant recipients. J Infect Dis. 2006;193:80–87.
Acott PD, O’Regan PA, Lee SH, et al. In vitro effect of cyclosporin A on primary and chronic BK polyoma virus infection in Vero E6 cells. Transpl Infect Dis. 2008;10:385–390.
Li YJ, Weng CH, Lai WC, et al. A suppressive effect of cyclosporine A on replication and noncoding control region activation of polyomavirus BK virus. Transplantation. 2010;89:299–306.
Hirsch HH, Yakhontova K, Lu M, et al. BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12. Am J Transplant. 2016;16:821–832.
Barraclough KA, Isbel NM, Staatz CE, et al. BK virus in kidney transplant recipients: the influence of immunosuppression. J Transplant. 2011;2011:750836.
Moens U, Subramaniam N, Johansen B, et al. A steroid hormone response unit in the late leader of the noncoding control region of the human polyomavirus BK confers enhanced host cell permissivity. J Virol. 1994;68:2398–2408.
Johnson HJ, Swan SK, Heim-Duthoy KL, et al. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther. 1998;63:512–518.
Meier-Kriesche HU, Shaw LM, Korecka M, et al. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit. 2000;22:27–30.
Fernandez E, Perez R, Hernandez A, et al. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011;3:53–72.
Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther. 2014;19:262–276.
Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol. 2002;17:141–149.
Grenda R, Watson A, Trompeter R, et al. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. Am J Transplant. 2010;10:828–836.
Offner G, Toenshoff B, Hocker B, et al. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Transplantation. 2008;86:1241–1248.
Staskewitz A, Kirste G, Tönshoff B, et al. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. Transplantation. 2001;71:638–644.
Henne T, Latta K, Strehlau J, et al. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation. 2003;76:1326–1330.
Brunkhorst LC, Fichtner A, Hocker B, et al. Efficacy and safety of an everolimus- vs. a mycophenolate mofetil-based regimen in pediatric renal transplant recipients. PLoS One. 2015;10:e0135439.
Hocker B, Zencke S, Krupka K, et al. Cytomegalovirus Infection in pediatric renal transplantation and the impact of chemoprophylaxis with (val-)ganciclovir. Transplantation. 2016;100:862–870.
Tönshoff B, Ettenger R, Dello Strologo L, et al. Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: results of a randomized trial. Am J Transplant. 2019;19:811–822.
Tönshoff B, Tedesco-Silva H, Ettenger R, et al. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal. Am J Transplant. 2021;21:123–137.
Smith F, Panek R, Kiberd BA. Screening to prevent polyoma virus nephropathy in kidney transplantation: a cost analysis. Am J Transplant. 2009;9:2177–2179.
Kiberd BA. Screening to prevent polyoma virus nephropathy: a medical decision analysis. Am J Transplant. 2005;5:2410–2416.
Wong G, Myint TM, Lee YJ, et al. Economic evaluation of screening for polyomavirus infection in kidney transplant recipients: a cost-utility analysis. Transplant Direct. 2022;8:e1318.
de Weerd AE, Betjes MGH. ABO-incompatible kidney transplant outcomes: a meta-analysis. Clin J Am Soc Nephrol. 2018;13:1234–1243.
Nguyen K, Diamond A, Carlo AD, et al. Characterization of kidney retransplantation following graft failure due to BK virus nephropathy. J Surg Res. 2022;269:110–118.
Ramos E, Vincenti F, Lu WX, et al. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation. 2004;77:131–133.
Huang J, Danovitch G, Pham PT, et al. Kidney retransplantation for BK virus nephropathy with active viremia without allograft nephrectomy. J Nephrol. 2015;28:773–777.
Cooper JE, Huskey J, Chan L, et al. Preemptive retransplant for BK virus nephropathy without concurrent transplant nephrectomy. Transplantation. 2010;90:331–332.